Metoclopramide NDC 50228-233

NDC codes

FDA NDC Directory

Product NDC (as listed)50228-233Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50228-0233Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
50228-233-01	50228023301	100 TABLET in 1 BOTTLE (50228-233-01)Marketed from Feb 12, 2025
50228-233-05	50228023305	500 TABLET in 1 BOTTLE (50228-233-05)Marketed from Feb 12, 2025
50228-233-10	50228023310	1000 TABLET in 1 BOTTLE (50228-233-10)Marketed from Feb 12, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Metoclopramide
Generic name (nonproprietary): metoclopramide
Active ingredients: Metoclopramide hydrochloride — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: ScieGen Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 072215
Marketing start: Feb 12, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Dopamine D2 Antagonists (Mechanism)
Identifiers: Product ID 50228-233_50b47676-8433-bfb9-e063-6394a90a124cSPL ID 50b47676-8433-bfb9-e063-6394a90a124cSPL set ID b16ad17c-eeea-407e-91e4-36506e9aa698RxCUI 311666, 311668UNII W1792A2RVDUPC 0350228232050, 0350228233057
Pharmacologic class: Dopamine-2 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N450228023301 followed by a unit qualifier and the quantity

Package 50228-0233-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 30, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. ( 1 ) Relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 ) Limitations of Use: Metoclopramide tablets have not been shown to be safe and effective for the treatment of gastroesophageal reflux for longer than 12 weeks. ( 1 , 5.1 ) Metoclopramide tablets are not recommended for use in pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates. ( 1 , 8.4 ) Metoclopramide tablets are indicated for th…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 072215

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 072215
Product	Strength	Form · route	Labeler	Product NDC
Metoclopramide	Metoclopramide hydrochloride 5 mg/1	TabletOral	NuCare Pharamceuticals, Inc.	68071-3924
Metoclopramide	Metoclopramide hydrochloride 5 mg/1	TabletOral	ScieGen Pharmaceuticals, Inc.	50228-232